AstraZeneca's anticoagulant reversal agent Andexxa was given an accelerated approval by the FDA in 2018, but the company's plan to get that upgraded to a full approval is facing some pushback.
Karen L. Hassenplug, Pharm.D.; Jill S. Burkiewicz, Pharm.D., BCPS; Terri L. Jackson, Ph.D., B.S.Pharm.; Laura R. Peppers, Pharm.D., BCPS Identifying baseline ...
India Glycols Ltd. key Products/Revenue Segments include Ethyl Alcohol, Glycol, Power, Chemical Product, Nutraceuticals, Gases Industrial, Guar Gum Powder & Derivatives, Other Operating Revenue, Sale ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback